Anavex (AVXL) urges backing six board nominees on white card
Rhea-AI Filing Summary
Anavex Life Sciences Corp. reported that its Board’s Executive Committee has mailed a letter to stockholders regarding the 2026 Annual Meeting of Stockholders and launched a dedicated website, www.VoteAnavex.com, which provides information about the meeting, the proxy process, and the company’s director nominees.
The letter encourages stockholders to vote the WHITE proxy card “FOR” six director nominees standing for election at the 2026 Annual Meeting. The Annual Meeting is scheduled for September 24, 2026, and stockholders of record at the close of business on July 31, 2026 are entitled to vote. The company also highlights where to find its definitive proxy statement and related materials filed with the SEC.
Positive
- None.
Negative
- None.
Filing Explained
The proxy campaign is active, but the director election remains pending and the accompanying materials are furnished, not filed.
The filing places the 2026 director election in an active solicitation stage: six nominees are being presented to stockholders, while the vote remains pending.
The immediate structural effect is a pending governance decision for eligible common stockholders, rather than an executed board reconstitution.
Under Item 7.01, the company furnishes the press release and stockholder letter as Regulation FD disclosure.
The filing expressly says this Item 7.01 information, including the exhibits, is not deemed filed for Section 18 purposes and is not incorporated by reference into other filings unless specifically referenced.
The next state change to watch is the annual-meeting vote, because the current filing establishes solicitation but not its result.
8-K Event Classification
Key Figures
Key Terms
Regulation FD regulatory
WHITE proxy card financial
definitive proxy statement regulatory
forward-looking statements regulatory
participants regulatory
FAQ
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area
Code: 1-
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On August 17, 2026, Anavex Life Sciences Corp. (“Anavex” or the “Company”) issued a press release (the “Press Release”) announcing the mailing of a letter to stockholders (the “Stockholder Letter”) regarding the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) and the launch of a website, www.voteanavex.com, which contains information related to the Annual Meeting.
Copies of the Press Release and the Stockholder Letter are furnished as Exhibits 99.1 and 99.2 to this Current Report and are incorporated herein by reference.
The information included in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 17, 2026. | |
| 99.2 | Stockholder Letter dated August 17, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | ||
| Date: August 17, 2026 | By: | /s/ Sandra Boenisch, CPA, CGA |
| Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer | ||
EXHIBIT 99.1
Anavex Life Sciences Mails Letter to Stockholders Reinforcing
Relevant Experience of All Six Director Nominees
Launches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees
and How to Vote at the Annual Meeting of Stockholders
NEW YORK, NY, August 17, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that the Executive Committee of the Anavex Board of Directors (the “Executive Committee”) has mailed a letter to stockholders encouraging them to vote the WHITE proxy card ”FOR” all six of Anavex’s highly qualified directors standing for election at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).
The full text of the letter being mailed to stockholders has been filed with the U.S. Security and Exchange Commission (SEC) and is available at www.VoteAnavex.com along with voting instructions and other information about the Annual Meeting. The letter highlights the following six highly qualified, independent director nominees and the complementary skills and experience each nominee brings:
| ● | Dr. Jiong Ma, Ph.D. brings deep financial, transactional and capital markets expertise to the Board, with substantial experience investing in, partnering with and working with management teams to set strategy for disruptive technology and life sciences companies to shape the business, accelerate growth and drive long-term shareholder value. |
| ● | Dr. Peter Donhauser, D.O. brings critical, relevant experience to the Board as clinical expert leading research across numerous trials for some of the world’s leading global pharmaceutical companies. |
| ● | Dr. Axel Paeger, M.D., MBA, MBI is a medically trained executive leader who brings deep experience in healthcare to the Board as founder of a leading healthcare provider in Europe. |
| ● | Gautam Patel, MBA (new independent candidate): The Executive Committee believes Mr. Patel is qualified to serve as a member of the Board because he brings extensive capital allocation, investment and financial advisory expertise to the Board, with a proven track record of executing growth-focused investments and guiding corporate strategy across the life sciences, financial services and technology sectors. |
| ● | Dr. Adrian Senderowicz, M.D. (new independent candidate): The Executive Committee believes Dr. Senderowicz is qualified to serve as a member of the Board because he brings deep drug development, clinical research and global regulatory expertise to the Board, with a proven track record of advancing novel therapeutics through critical international approvals to drive growth and long-term value. |
1
| ● | Dr. Claus van der Velden, Ph.D. brings accounting and executive financial experience to the Board that provides critical perspective on accounting and capital allocation strategy. |
The Annual Meeting will be held on September 24, 2026, and stockholders of record as of close of business on July 31, 2026 are entitled to vote.
If you have any questions or require any assistance with voting your shares, please call:
Innisfree M&A Incorporated
500 Fifth Avenue, 21st Floor
New York, NY 10110
Stockholders may call toll-free at (877) 750-0831
Brokers, banks and other nominees may call collect at (212) 750-5833
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s plans, strategies and expectations regarding the 2026 Annual Meeting, director nominations, the proxy solicitation, the Company’s go-forward strategy, clinical development programs, business prospects, and potential actions of the Board and the Executive Committee, are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including the risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.
2
Important Additional Information and Where to Find It
The Company has filed a definitive proxy statement on Schedule 14A, an accompanying WHITE proxy card, and other relevant documents with the SEC in connection with the solicitation of proxies from the Company’s stockholders for the 2026 Annual Meeting. THE COMPANY’S STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Stockholders are able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents that the Company files with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at www.anavex.com.
Certain Information Regarding Participants
The Company, its directors and certain of its executive officers may be deemed to be “participants” (as defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the matters to be considered at the 2026 Annual Meeting. Information regarding the names of the Company’s directors and executive officers and certain other individuals and their direct or indirect interests in the Company, by security holdings or otherwise, is set forth in the sections entitled “Compensation of Directors,” “Executive Compensation,” and “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (available here), and any subsequent filings on Forms 3, 4 and 5 filed with the SEC. Additional information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting which has been filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov.
Investor Relations:
SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com
Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com
For Media:
Collected Strategies
Nick Lamplough / Dylan O’Keefe
AVXL-CS@collectedstrategies.com
3
EXHIBIT 99.2
